EE9700137A - Peptiidide ja proteiinide aerosoolvormid - Google Patents

Peptiidide ja proteiinide aerosoolvormid

Info

Publication number
EE9700137A
EE9700137A EE9700137A EE9700137A EE9700137A EE 9700137 A EE9700137 A EE 9700137A EE 9700137 A EE9700137 A EE 9700137A EE 9700137 A EE9700137 A EE 9700137A EE 9700137 A EE9700137 A EE 9700137A
Authority
EE
Estonia
Prior art keywords
peptides
proteins
aerosol forms
aerosol
forms
Prior art date
Application number
EE9700137A
Other languages
English (en)
Other versions
EE03590B1 (et
Inventor
B�ckstr�m Kjell
Dahlb�ck Magnus
Johansson Ann
K�llstrand G�ran
Lindqvist Elisabet
Original Assignee
Astra Aktiebolag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE9404467A external-priority patent/SE9404467D0/xx
Priority claimed from SE9502453A external-priority patent/SE9502453D0/xx
Application filed by Astra Aktiebolag filed Critical Astra Aktiebolag
Publication of EE9700137A publication Critical patent/EE9700137A/et
Publication of EE03590B1 publication Critical patent/EE03590B1/et

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pulmonology (AREA)
  • Zoology (AREA)
  • Otolaryngology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Toxicology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
EE9700137A 1994-12-22 1995-12-19 Peptiidide ja proteiinide aerosoolvormid EE03590B1 (et)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE9404467A SE9404467D0 (sv) 1994-12-22 1994-12-22 Drug formulations
SE9502453A SE9502453D0 (sv) 1995-07-06 1995-07-06 Drug formulations
PCT/SE1995/001540 WO1996019197A1 (en) 1994-12-22 1995-12-19 Aerosol formulations of peptides and proteins

Publications (2)

Publication Number Publication Date
EE9700137A true EE9700137A (et) 1997-12-15
EE03590B1 EE03590B1 (et) 2002-02-15

Family

ID=26662195

Family Applications (1)

Application Number Title Priority Date Filing Date
EE9700137A EE03590B1 (et) 1994-12-22 1995-12-19 Peptiidide ja proteiinide aerosoolvormid

Country Status (33)

Country Link
US (1) US6524557B1 (et)
EP (2) EP0797431B1 (et)
JP (2) JP3862178B2 (et)
KR (1) KR100428281B1 (et)
CN (1) CN1088581C (et)
AR (1) AR002013A1 (et)
AT (1) ATE217787T1 (et)
AU (1) AU702879B2 (et)
BR (1) BR9510501A (et)
CA (1) CA2206736C (et)
CZ (1) CZ288145B6 (et)
DE (1) DE69526801T2 (et)
DK (1) DK0797431T3 (et)
EE (1) EE03590B1 (et)
ES (1) ES2176355T3 (et)
FI (1) FI119413B (et)
HK (1) HK1003503A1 (et)
HU (1) HU227790B1 (et)
IL (1) IL116458A (et)
IS (1) IS1810B (et)
MX (1) MX9704545A (et)
MY (1) MY120664A (et)
NO (1) NO316105B1 (et)
NZ (1) NZ298167A (et)
PL (1) PL182560B1 (et)
PT (1) PT797431E (et)
RU (1) RU2175866C2 (et)
SA (1) SA95160483B1 (et)
SK (1) SK284346B6 (et)
TR (1) TR199501669A1 (et)
TW (1) TW398978B (et)
UA (1) UA42047C2 (et)
WO (1) WO1996019197A1 (et)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6632456B1 (en) * 1993-06-24 2003-10-14 Astrazeneca Ab Compositions for inhalation
US6794357B1 (en) 1993-06-24 2004-09-21 Astrazeneca Ab Compositions for inhalation
BR9510510A (pt) * 1994-12-22 1998-07-07 Astra Ab Formulação em aerossol farmacêutica uso da mesma e processos para fabricação da mesma para tratamento de um paciente carente de terapia
US5874481A (en) * 1995-06-07 1999-02-23 Alliance Pharmaceutical Corp. Fluorochemical solutions for the delivery of lipophilic pharmaceutical agents
MEP4108A (xx) * 1997-09-29 2010-02-10 Inhale Therapeutic Syst Perforisane mikročestice i postupci za njihovu primjenu
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
US6086376A (en) * 1998-01-30 2000-07-11 Rtp Pharma Inc. Dry aerosol suspension of phospholipid-stabilized drug microparticles in a hydrofluoroalkane propellant
US6017545A (en) * 1998-02-10 2000-01-25 Modi; Pankaj Mixed micellar delivery system and method of preparation
US6221378B1 (en) * 1998-02-10 2001-04-24 Generex Pharmaceuticals Incorporated Mixed micellar delivery system and method of preparation
US7070799B1 (en) 1998-02-10 2006-07-04 Generex Pharmaceuticals, Inc. Method for administering insulin to the buccal region
US6180142B1 (en) 1998-08-21 2001-01-30 The Regents Of The University Of California Reduction of surfactant inactivation in pulmonary surfactant therapy
MA25590A1 (fr) * 1998-09-14 2002-12-31 Inhale Therapeutic Syst Agent actif de delivraison de poudre seche
US7087215B2 (en) * 1998-12-21 2006-08-08 Generex Pharmaceuticals Incorporated Methods of administering and enhancing absorption of pharmaceutical agents
US7658938B2 (en) 1999-02-22 2010-02-09 Merrion Reasearch III Limited Solid oral dosage form containing an enhancer
US7112341B1 (en) 1999-04-13 2006-09-26 Nektar Therapeutics Pulmonary administration of dry powder formulations for treating infertility
EP1064934A1 (en) 1999-06-30 2001-01-03 Applied Research Systems ARS Holding N.V. GRF-containing lyophilized pharmaceutical composition
WO2001032201A2 (en) * 1999-10-29 2001-05-10 Eli Lilly And Company A pharmaceutical composition having high cell membrane permeability
WO2001072278A2 (en) * 2000-03-30 2001-10-04 Generex Pharmaceuticals Inc. Method for administering insulin to the buccal region
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
MXPA03001092A (es) 2000-08-07 2003-09-25 Nektar Therapeutics Al Corp Polvos de proteina de haz de 4 helices secados por rocio, inhalables, que tienen agregacion minimizada.
EP2168571B1 (en) 2000-11-30 2018-08-22 Vectura Limited Particles for use in a Pharmaceutical Composition
EP2283818B1 (en) 2000-11-30 2017-08-02 Vectura Limited Method of making particles for use in a pharmaceutical composition
EP1337241B1 (en) * 2000-11-30 2008-01-02 Vectura Limited Method of preparing microparticles for use in pharmaceutical compositions for inhalation
JP2005501810A (ja) 2001-03-22 2005-01-20 バテル メモリアル インスティチュート ポリマーおよび懸濁粒子を含有する電気流体力学的噴霧用の液体形成物
HU229798B1 (en) * 2001-03-30 2014-07-28 Jagotec Ag Medical aerosol compositions and process for their preparation
JP2004528339A (ja) * 2001-04-26 2004-09-16 ネクター セラピューティクス 気道に対して又は気道を介して高分子を送達するための新規方法及び組成物
GB0114033D0 (en) * 2001-06-09 2001-08-01 Innovata Biomed Ltd Process
US20030064033A1 (en) * 2001-08-16 2003-04-03 Brown Larry R. Propellant-based microparticle formulations
EP1944016A1 (en) 2001-08-16 2008-07-16 Baxter International Inc. Propellant-based microparticle formulatons
US7368102B2 (en) 2001-12-19 2008-05-06 Nektar Therapeutics Pulmonary delivery of aminoglycosides
US20030178022A1 (en) * 2001-12-21 2003-09-25 Chiesi Farmaceutici S.P.A. Pressurized metered dose inhaler (PMDI) actuators and medicinal aerosol solution formulation products comprising therse actuators
JP2005514440A (ja) 2001-12-21 2005-05-19 スリーエム イノベイティブ プロパティズ カンパニー アミドおよび／またはエステルを含有する、賦形剤化合物を含む、医用エアロゾル組成物
US7718162B2 (en) 2001-12-21 2010-05-18 3M Innovative Properties Company Medicinal aerosol compositions with a functionalized polyethyleneglycol excipient
DE10205087A1 (de) * 2002-02-07 2003-08-21 Pharmatech Gmbh Cyclodextrine als Suspensionsstabilisatoren in druckverflüssigten Treibmitteln
US20030185762A1 (en) * 2002-03-22 2003-10-02 Cowan Siu Man L. Highly aqueous liquid carrier formulations
SE524990C2 (sv) * 2002-04-12 2004-11-09 Microdrug Ag Preparation av terapeutiskt torrt pulver samt förfarande för uppdelning och spridning i luft av medicinskt pulver
SE525027C2 (sv) * 2002-04-12 2004-11-16 Microdrug Ag Anordning utgörande en pulverlufthyvel
DE60311665T2 (de) * 2002-08-23 2007-10-25 Schering Corp. Pharmazeutische zusammensetzungen
GB0226274D0 (en) * 2002-11-11 2002-12-18 Medpharm Ltd Metered dose inhalation preparations
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
EP1599184A4 (en) * 2003-02-04 2009-06-24 Chrysalis Tech Inc FULLY HALOGENATED FLUOROCARBON HYDROGEN AND HYDROFLUOROCHLOROUS HYDROGEN FUELS AND METHOD FOR THE PRODUCTION AND USE THEREOF
AR043972A1 (es) * 2003-04-02 2005-08-17 Ares Trading Sa Formulaciones farmaceuticas de fsh y lh
AU2005247410A1 (en) * 2004-05-20 2005-12-08 Discovery Laboratories, Inc. Methods , systems and devices for noninvasive pulmonary delivery
EP1789075A4 (en) * 2004-08-25 2009-07-01 Uab Research Foundation ABSORPTION ENHANCER FOR DRUG ADMINISTRATION
US20090047347A1 (en) * 2005-07-29 2009-02-19 Aegis Therapeutics, Inc. Compositions for Drug Administration
US20060046969A1 (en) * 2004-08-25 2006-03-02 Aegis Therapeutics Llc Antibacterial compositions for drug administration
US8268791B2 (en) * 2004-08-25 2012-09-18 Aegis Therapeutics, Llc. Alkylglycoside compositions for drug administration
US9895444B2 (en) 2004-08-25 2018-02-20 Aegis Therapeutics, Llc Compositions for drug administration
US20060046962A1 (en) 2004-08-25 2006-03-02 Aegis Therapeutics Llc Absorption enhancers for drug administration
US9114069B2 (en) * 2004-08-25 2015-08-25 Aegis Therapeutics, Llc Antibacterial compositions for drug administration
US20140162965A1 (en) 2004-08-25 2014-06-12 Aegis Therapeutics, Inc. Compositions for oral drug administration
US8642564B2 (en) * 2004-08-25 2014-02-04 Aegis Therapeutics, Llc Compositions for drug administration
CA2581564C (en) * 2004-10-01 2017-01-03 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin Compounds that modulate trh actions
CN1301747C (zh) * 2004-11-30 2007-02-28 深圳市海王英特龙生物技术股份有限公司 一种蛋白药物微囊及其吸入性气雾剂
US8028697B2 (en) 2005-04-28 2011-10-04 Trudell Medical International Ventilator circuit and method for the use thereof
WO2007008427A2 (en) * 2005-07-08 2007-01-18 Xemplar Pharmaceuticals, Llc Aerosol compositions and methods
TWI299993B (en) 2005-12-15 2008-08-21 Dev Center Biotechnology Aqueous inhalation pharmaceutical composition
MX2008012678A (es) * 2006-04-07 2008-12-17 Merrion Res Iii Ltd Forma de dosis oral solida que contiene un mejorador.
US20090326193A1 (en) * 2006-06-23 2009-12-31 Aegis Therapeutics Llc Stabilizing alkylglycoside compositions and methods thereof
US7425542B2 (en) * 2006-06-23 2008-09-16 Aegis Therapeutics, Inc. Stabilizing alkylglycoside compositions and methods thereof
US8173594B2 (en) * 2006-06-23 2012-05-08 Aegis Therapeutics, Llc Stabilizing alkylglycoside compositions and methods thereof
US7998927B2 (en) * 2006-06-23 2011-08-16 Aegis Therapeutics, Llc Stabilizing alkylglycoside compositions and methods thereof
US8084022B2 (en) * 2006-06-23 2011-12-27 Aegis Therapeutics, Llc Stabilizing alkylglycoside compositions and methods thereof
US8226949B2 (en) 2006-06-23 2012-07-24 Aegis Therapeutics Llc Stabilizing alkylglycoside compositions and methods thereof
JP5102833B2 (ja) 2006-07-24 2012-12-19 バイオレクシス ファーマシューティカル コーポレーション エキセンディン融合タンパク質
ATE544759T1 (de) 2007-07-21 2012-02-15 Albany Molecular Res Inc 5-pyridinon-substituierte indazole und pharmazeutische zusammensetzungen davon
CA2722611A1 (en) 2007-11-21 2009-05-28 Decode Genetics Ehf Biaryl pde4 inhibitors for treating pulmonary and cardiovascular disorders
CA2727055C (en) 2008-01-11 2016-12-20 Albany Molecular Research, Inc. (1-azinone) -substituted pyridoindoles as mch antagonists
HUE028653T2 (en) 2008-03-17 2016-12-28 Discovery Lab Inc Respiratory circuit adapter and direct aerosol delivery system
US20090258865A1 (en) 2008-03-28 2009-10-15 Hale Biopharma Ventures, Llc Administration of benzodiazepine compositions
MX2010012201A (es) * 2008-05-07 2011-05-30 Merrion Res Iii Ltd Composiciones de péptidos y procedimientos de preparación de las mismas.
CA2683353C (en) 2008-10-22 2015-12-15 Trudell Medical International Modular aerosol delivery system
WO2010059836A1 (en) 2008-11-20 2010-05-27 Decode Genetics Ehf Substituted aza-bridged bicyclics for cardiovascular and cns disease
US8440631B2 (en) 2008-12-22 2013-05-14 Aegis Therapeutics, Llc Compositions for drug administration
WO2010084499A2 (en) 2009-01-26 2010-07-29 Israel Institute For Biological Research Bicyclic heterocyclic spiro compounds
JP2012518686A (ja) * 2009-02-25 2012-08-16 メリオン・リサーチ・Ｉｉｉ・リミテッド ビスホスホネート類の組成物および薬物送達
WO2011075611A1 (en) * 2009-12-18 2011-06-23 Aegis Therapeutics, Llc Compositions and methods for non-invasive treatment of chronic complication of diabetes
US20110182985A1 (en) * 2010-01-28 2011-07-28 Coughlan David C Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof
US9089484B2 (en) * 2010-03-26 2015-07-28 Merrion Research Iii Limited Pharmaceutical compositions of selective factor Xa inhibitors for oral administration
US8802058B2 (en) * 2010-04-19 2014-08-12 Gelmed, Llc Pharmaceutical compositions and methods for administering the same
WO2011138802A1 (en) * 2010-05-07 2011-11-10 Sun Pharma Advanced Research Company Ltd., Injection solution
WO2012094598A2 (en) 2011-01-07 2012-07-12 Merrion Research Iii Limited Pharmaceutical compositions of iron for oral administration
CN103796656A (zh) 2011-06-14 2014-05-14 哈尔生物药投资有限责任公司 苯二氮卓的投与
CN103874483B (zh) 2011-10-11 2017-09-12 奇斯药制品公司 包衣了脂肪酸的β‑激动剂的晶体微粒
SG10201604104PA (en) 2011-10-25 2016-07-28 Prothena Therapeutics Ltd Antibody formulations and methods
RU2657523C2 (ru) * 2011-11-03 2018-06-14 Олег Петрович Жирнов Фармацевтический аэрозольный состав ингибиторов протеаз с озон-сберегающим пропеллентом и его получение
DK3212212T3 (da) 2014-10-31 2020-12-21 Univ Monash Pulverformulering
WO2016120378A1 (en) 2015-01-29 2016-08-04 Novo Nordisk A/S Tablets comprising glp-1 agonist and enteric coating
WO2019157099A1 (en) 2018-02-06 2019-08-15 Aegis Therapeutics, Llc Intranasal epinephrine formulations and methods for the treatment of disease
CA3093340A1 (en) 2018-03-20 2019-09-26 Icahn School Of Medicine At Mount Sinai Kinase inhibitor compounds and compositions and methods of use
CA3111275A1 (en) 2018-09-06 2020-03-12 Innopharmascreen Inc. Methods and compositions for treatment of asthma or parkinson's disease
CA3124700A1 (en) 2018-12-31 2020-07-09 Icahn School Of Medicine At Mount Sinai Kinase inhibitor compounds and compositions and methods of use

Family Cites Families (115)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE556587A (et) 1957-01-31 1957-04-11
US2992645A (en) * 1958-05-06 1961-07-18 Benger Lab Ltd Disperser for powders
GB1063512A (en) 1962-11-30 1967-03-30 Benger Lab Ltd Aerosols
GB1144905A (en) * 1965-03-25 1969-03-12 Fisons Pharmaceuticals Ltd Substituted bis-(2-carboxy-chromonyl-oxy) derivatives and preparation and pharmaceutical compositions thereof
GB1230472A (et) 1967-07-10 1971-05-05
GB1242211A (en) 1967-08-08 1971-08-11 Fisons Pharmaceuticals Ltd Pharmaceutical composition
GB1569611A (en) 1976-01-23 1980-06-18 Fisons Ltd Pelletised or granular medicament formulation
GB1520247A (en) 1974-08-10 1978-08-02 Fisons Ltd Pelletised medicament formulations
GB1554157A (en) 1975-06-13 1979-10-17 Takeda Chemical Industries Ltd Stable insulin preparation for intra nasal administration
GB1527605A (en) 1975-08-20 1978-10-04 Takeda Chemical Industries Ltd Insulin preparation for intranasal administration
DE2750090A1 (de) * 1976-11-19 1978-06-01 Sandoz Ag Neue verabreichungsformen fuer organische verbindungen
FR2372632A1 (fr) 1976-12-03 1978-06-30 Riker Laboratoires Nouveau medicament a base d'heparine administrable par voie tracheo-bronchique et alveolaire
SE7812207L (sv) 1977-12-01 1979-06-02 Welsh Nat School Med Apparat, forfarande och framstellda produkter for anvendning vid administration av antihistaminer
JPS6034925B2 (ja) 1979-07-31 1985-08-12 帝人株式会社 持続性鼻腔用製剤およびその製造法
JPS5795920A (en) 1980-12-04 1982-06-15 Teijin Ltd Remedy for respiratory disease
US4900730A (en) 1981-01-14 1990-02-13 Toyo Jozo Co., Ltd. Preparation which promotes the absorption of peptides
SE438261B (sv) * 1981-07-08 1985-04-15 Draco Ab Anvendning i dosinhalator av ett perforerat membran
CY1492A (en) * 1981-07-08 1990-02-16 Draco Ab Powder inhalator
US5260306A (en) * 1981-07-24 1993-11-09 Fisons Plc Inhalation pharmaceuticals
JPS59163313A (ja) 1983-03-09 1984-09-14 Teijin Ltd 経鼻投与用ペプチドホルモン類組成物
DD261096A1 (de) 1983-05-20 1988-10-19 Frithjof Von Rottkay Verfahren zur inhalativen applikation biologisch aktiver peptide
US4746508A (en) 1983-06-06 1988-05-24 Beth Israel Hospital Assn. Drug administration
US4548922A (en) 1983-06-06 1985-10-22 Beth Israel Hospital Drug administration
US4959358A (en) 1983-06-06 1990-09-25 Beth Israel Hospital Assn. Drug administration
DE3323389A1 (de) 1983-06-29 1985-01-10 B. Braun Melsungen Ag, 3508 Melsungen Auf schleimhaeute des mundes, der nase und/oder des rachens wirkende arzneimittel auf der basis von heparin und tensiden
DE3326089A1 (de) 1983-07-20 1985-02-07 Gödecke AG, 1000 Berlin Zur inhalation bestimmte darreichungsform von calcium-antagonisten
US4963367A (en) 1984-04-27 1990-10-16 Medaphore, Inc. Drug delivery compositions and methods
US4794000A (en) 1987-01-08 1988-12-27 Synthetic Blood Corporation Coacervate-based oral delivery system for medically useful compositions
US4849405A (en) 1984-05-09 1989-07-18 Synthetic Blood Corporation Oral insulin and a method of making the same
US5288498A (en) * 1985-05-01 1994-02-22 University Of Utah Research Foundation Compositions of oral nondissolvable matrixes for transmucosal administration of medicaments
US4537772A (en) * 1984-05-02 1985-08-27 Merck & Co., Inc. Enhancing absorption of drugs from gastrointestinal tract using acylcarnitines
JPS61267528A (ja) 1984-11-26 1986-11-27 Yamanouchi Pharmaceut Co Ltd 吸収促進剤を含有するカルシトニン経鼻剤
SE448277B (sv) * 1985-04-12 1987-02-09 Draco Ab Indikeringsanordning vid en doseringsanordning for lekemedel
CA1274774A (en) 1985-04-15 1990-10-02 Kenneth S. Su Method for administering insulin
US5122127A (en) * 1985-05-01 1992-06-16 University Of Utah Apparatus and methods for use in administering medicaments by direct medicament contact to mucosal tissues
DE3686025T2 (de) 1985-05-22 1993-01-07 Liposome Technology Inc Verfahren und system zum einatmen von liposomen.
US4731360A (en) * 1985-08-16 1988-03-15 Merck & Co., Inc. Acylcarnitines as absorption-enhancing agents for drug delivery through mucous membranes of the nasal, buccal, sublingual and vaginal compartments
US4847298A (en) 1985-08-16 1989-07-11 Merck & Co., Inc. Acylcarnitines as absorption-enhancing agents for drug delivery through mucous membranes of the nasal, buccal, sublingual and vaginal compartments
IL77186A0 (en) 1985-11-29 1986-04-29 Touitou Elka Pharmaceutical insulin composition
IT1204826B (it) 1986-03-04 1989-03-10 Chiesi Farma Spa Composizioni farmaceutiche per inalazione
SE453566B (sv) * 1986-03-07 1988-02-15 Draco Ab Anordning vid pulverinhalatorer
JPS632932A (ja) 1986-06-23 1988-01-07 Teijin Ltd 経鼻投与用粉末状組成物
US4926852B1 (en) * 1986-06-23 1995-05-23 Univ Johns Hopkins Medication delivery system phase one
JP2765700B2 (ja) * 1986-08-11 1998-06-18 イノベータ・バイオメド・リミテツド マイクロカプセルを含有する医薬調合物
AU627147B2 (en) 1986-10-22 1992-08-20 Peter Alestrom Production of human parathyroid hormone from microorganisms
NZ222907A (en) 1986-12-16 1990-08-28 Novo Industri As Preparation for intranasal administration containing a phospholipid absorption enhancing system
US5179079A (en) 1986-12-16 1993-01-12 Novo Nordisk A/S Nasal formulation and intranasal administration therewith
GB8712176D0 (en) 1987-05-22 1987-06-24 Cosmas Damian Ltd Drug delivery system
GB8723846D0 (en) 1987-10-10 1987-11-11 Danbiosyst Ltd Bioadhesive microsphere drug delivery system
ATE99543T1 (de) 1987-10-15 1994-01-15 Syntex Inc Pulverfoermige zubereitungen zur intranasalen verabreichung von polypeptiden.
JPH01117825A (ja) 1987-10-28 1989-05-10 Sanwa Kagaku Kenkyusho Co Ltd 鼻くう、副鼻くう投与用製剤及びその使用方法並びにその形状及び使用器具
EP0360340A1 (en) 1988-09-19 1990-03-28 Akzo N.V. Composition for nasal administration containing a peptide
US5997856A (en) 1988-10-05 1999-12-07 Chiron Corporation Method and compositions for solubilization and stabilization of polypeptides, especially proteins
JPH02104531A (ja) 1988-10-14 1990-04-17 Toyo Jozo Co Ltd 経鼻投与用生理活性ペプチド組成物
US5225183A (en) * 1988-12-06 1993-07-06 Riker Laboratories, Inc. Medicinal aerosol formulations
GB8828477D0 (en) 1988-12-06 1989-01-05 Riker Laboratories Inc Medical aerosol formulations
US5006343A (en) 1988-12-29 1991-04-09 Benson Bradley J Pulmonary administration of pharmaceutically active substances
GB8900267D0 (en) 1989-01-06 1989-03-08 Riker Laboratories Inc Narcotic analgesic formulations and apparatus containing same
US4994439A (en) 1989-01-19 1991-02-19 California Biotechnology Inc. Transmembrane formulations for drug administration
US5011678A (en) 1989-02-01 1991-04-30 California Biotechnology Inc. Composition and method for administration of pharmaceutically active substances
ATE138071T1 (de) 1989-02-17 1996-06-15 Liposome Co Inc Lipidhilfstoffe für verabreichung durch die nase und örtliche anwendung
IT8920486A0 (it) 1989-05-12 1989-05-12 Isf Spa Composizioni farmaceutiche.
US5176132A (en) * 1989-05-31 1993-01-05 Fisons Plc Medicament inhalation device and formulation
US5174988A (en) 1989-07-27 1992-12-29 Scientific Development & Research, Inc. Phospholipid delivery system
JP2642486B2 (ja) 1989-08-04 1997-08-20 田辺製薬株式会社 難溶性薬物の超微粒子化法
GB8921222D0 (en) 1989-09-20 1989-11-08 Riker Laboratories Inc Medicinal aerosol formulations
US5707644A (en) 1989-11-04 1998-01-13 Danbiosyst Uk Limited Small particle compositions for intranasal drug delivery
US5376386A (en) * 1990-01-24 1994-12-27 British Technology Group Limited Aerosol carriers
GB9001635D0 (en) * 1990-01-24 1990-03-21 Ganderton David Aerosol carriers
DE4003272A1 (de) 1990-02-03 1991-08-08 Boehringer Ingelheim Kg Neue treibgasmischungen und ihre verwendung in arzneimittelzubereitungen
AU654813B2 (en) 1990-03-23 1994-11-24 Minnesota Mining And Manufacturing Company The use of soluble fluorosurfactants for the preparation of metered-dose aerosol formulations
US5118494A (en) 1990-03-23 1992-06-02 Minnesota Mining And Manufacturing Company Use of soluble fluorosurfactants for the preparation of metered-dose aerosol formulations
JPH05963A (ja) 1990-04-13 1993-01-08 Toray Ind Inc ポリペプチド類組成物
US5192548A (en) 1990-04-30 1993-03-09 Riker Laboratoires, Inc. Device
AU7908791A (en) 1990-05-08 1991-11-27 Liposome Technology, Inc. Direct spray-dried drug/lipid powder composition
EP0532546B1 (en) 1990-05-10 1998-03-18 Bechgaard International Research And Development A/S A pharmaceutical preparation containing n-glycofurols and n-ethylene glycols
GB9010742D0 (en) 1990-05-14 1990-07-04 Quadrant Bioresources Ltd Stabilization of biological macromolecular substances
JPH0441421A (ja) 1990-06-07 1992-02-12 Taisho Pharmaceut Co Ltd 肺吸収組成物
US5126123A (en) * 1990-06-28 1992-06-30 Glaxo, Inc. Aerosol drug formulations
SE9002895D0 (sv) 1990-09-12 1990-09-12 Astra Ab Inhalation devices for dispensing powders i
JPH04149126A (ja) 1990-10-09 1992-05-22 Mitsubishi Kasei Corp 経粘膜投与用医薬組成物
IL99699A (en) 1990-10-10 2002-04-21 Autoimmune Inc Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes
GB9024365D0 (en) 1990-11-09 1991-01-02 Glaxo Group Ltd Medicaments
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
JP3507486B2 (ja) 1991-03-15 2004-03-15 アムジエン・インコーポレーテツド 顆粒球コロニー刺激因子の肺内投与
EP0656207B2 (en) 1991-06-10 2009-07-22 Schering Corporation Non-chlorofluorocarbon aerosol formulations
WO1993000951A1 (en) * 1991-07-02 1993-01-21 Inhale, Inc. Method and device for delivering aerosolized medicaments
US5744123A (en) * 1991-12-12 1998-04-28 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicaments
US5674471A (en) * 1991-12-12 1997-10-07 Glaxo Group Limited Aerosol formulations containing P134a and salbutamol
US5653962A (en) * 1991-12-12 1997-08-05 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicaments
US5320094A (en) * 1992-01-10 1994-06-14 The Johns Hopkins University Method of administering insulin
DE69306755T2 (de) 1992-01-21 1997-04-10 Stanford Res Inst Int Verbessertes verfahren zur herstellung von mikronisierter polypeptidarzneimitteln
US5352461A (en) * 1992-03-11 1994-10-04 Pharmaceutical Discovery Corporation Self assembling diketopiperazine drug delivery system
CA2094217A1 (en) 1992-04-17 1993-10-18 Yasutaka Igari Transmucosal therapeutic composition
ES2177544T3 (es) 1992-06-12 2002-12-16 Teijin Ltd Polvo ultrafinno para inhalar y metodo para su preparacion.
US5376359A (en) * 1992-07-07 1994-12-27 Glaxo, Inc. Method of stabilizing aerosol formulations
KR100291620B1 (ko) 1992-09-29 2001-10-24 추후제출 부갑상선호르몬의활성단편의폐를통한전달방법
US5364838A (en) 1993-01-29 1994-11-15 Miris Medical Corporation Method of administration of insulin
DE69426415T2 (de) * 1993-01-29 2001-07-26 Aradigm Corp., Hayward Intrapulmonares hormonabgabesystem
BE1006873A6 (nl) 1993-03-26 1995-01-10 Merkus Franciscus W H M Toedieningsformulering voor nasale insuline toediening.
WO1994023772A2 (en) * 1993-04-06 1994-10-27 Minnesota Mining And Manufacturing Company Deagglomerators for dry powder inhalers
IS1796B (is) * 1993-06-24 2001-12-31 Ab Astra Fjölpeptíð lyfjablanda til innöndunar sem einnig inniheldur eykjaefnasamband
US5661130A (en) 1993-06-24 1997-08-26 The Uab Research Foundation Absorption enhancers for drug administration
US5830853A (en) 1994-06-23 1998-11-03 Astra Aktiebolag Systemic administration of a therapeutic preparation
US5747445A (en) 1993-06-24 1998-05-05 Astra Aktiebolag Therapeutic preparation for inhalation
TW402506B (en) 1993-06-24 2000-08-21 Astra Ab Therapeutic preparation for inhalation
US5506203C1 (en) 1993-06-24 2001-02-06 Astra Ab Systemic administration of a therapeutic preparation
GB9314614D0 (en) * 1993-07-14 1993-08-25 Minnesota Mining & Mfg Dry powder inhalers
US5349947A (en) * 1993-07-15 1994-09-27 Newhouse Michael T Dry powder inhaler and process that explosively discharges a dose of powder and gas from a soft plastic pillow
US5514670A (en) 1993-08-13 1996-05-07 Pharmos Corporation Submicron emulsions for delivery of peptides
ES2218543T3 (es) 1994-03-07 2004-11-16 Nektar Therapeutics Procedimiento y preparacion para la administracion de insulina por via pulmonar.
US6051256A (en) 1994-03-07 2000-04-18 Inhale Therapeutic Systems Dispersible macromolecule compositions and methods for their preparation and use
US5451569A (en) * 1994-04-19 1995-09-19 Hong Kong University Of Science And Technology R & D Corporation Limited Pulmonary drug delivery system
US6165976A (en) * 1994-06-23 2000-12-26 Astra Aktiebolag Therapeutic preparation for inhalation
SE9404468D0 (sv) * 1994-12-22 1994-12-22 Astra Ab Powder formulations

Also Published As

Publication number Publication date
PL182560B1 (pl) 2002-01-31
PL320824A1 (en) 1997-11-10
DE69526801D1 (de) 2002-06-27
EP1180365A3 (en) 2003-06-25
US6524557B1 (en) 2003-02-25
ATE217787T1 (de) 2002-06-15
NO316105B1 (no) 2003-12-15
IL116458A0 (en) 1996-03-31
IS1810B (is) 2002-04-30
KR100428281B1 (ko) 2004-06-16
FI119413B (fi) 2008-11-14
UA42047C2 (uk) 2001-10-15
CN1171046A (zh) 1998-01-21
HUT77701A (hu) 1998-07-28
MX9704545A (es) 1997-10-31
PT797431E (pt) 2002-10-31
SK81397A3 (en) 1997-11-05
SK284346B6 (sk) 2005-02-04
DE69526801T2 (de) 2003-01-09
EP0797431A1 (en) 1997-10-01
NZ298167A (en) 1999-08-30
JP2006137776A (ja) 2006-06-01
IL116458A (en) 2001-01-11
IS4496A (is) 1997-06-04
WO1996019197A1 (en) 1996-06-27
NO972781L (no) 1997-06-16
EE03590B1 (et) 2002-02-15
TR199501669A1 (tr) 1997-03-21
CN1088581C (zh) 2002-08-07
AU702879B2 (en) 1999-03-11
JP3862178B2 (ja) 2006-12-27
FI972657A0 (fi) 1997-06-19
AR002013A1 (es) 1998-01-07
JPH10510827A (ja) 1998-10-20
CZ288145B6 (en) 2001-05-16
EP1180365A2 (en) 2002-02-20
CA2206736C (en) 2007-05-22
DK0797431T3 (da) 2002-08-19
NO972781D0 (no) 1997-06-16
AU4359196A (en) 1996-07-10
EP0797431B1 (en) 2002-05-22
TW398978B (en) 2000-07-21
HU227790B1 (en) 2012-03-28
FI972657A (fi) 1997-06-19
BR9510501A (pt) 1998-01-13
RU2175866C2 (ru) 2001-11-20
CA2206736A1 (en) 1996-06-27
HK1003503A1 (en) 1998-10-30
CZ194597A3 (en) 1997-10-15
ES2176355T3 (es) 2002-12-01
SA95160483B1 (ar) 2005-04-19
MY120664A (en) 2005-11-30

Similar Documents

Publication Publication Date Title
EE03590B1 (et) Peptiidide ja proteiinide aerosoolvormid
EP0785276A4 (en) MODIFICATION OF A PEPTIDE AND A PROTEIN
BR9607317A (pt) Peptídios e composição farmacêutica
BR9607318A (pt) Peptidos e composição farmacêutica
DK0799577T3 (da) Peptidblanding og produkter deraf
CY2010017I2 (el) Νεα πρωτεϊνη και μεθοδος παρασκευης αυτης
DE69434520D1 (de) Biotinylierung von proteinen
ID22807A (id) Hasil derifat 1-aril dan piridilpirazol untuk pestisida
FI963185A (fi) Hematopoieettinen proteiini ja materiaalit ja menetelmät sen valmistamiseksi
EP0704532A3 (en) Recombinant chimeric proteins and methods of using them
NO964758D0 (no) Anvendelse av von Willebrand-faktor og farmasöytiske preparater
KR960016892A (ko) 약제의 신독성 경감제
FI963334A0 (fi) Tyrosinaasista peräisin olevat eristetyt peptidit ja niiden käyttö
ID21034A (id) Protein kinase dan penggunaannya
NO971505D0 (no) Trofinin og trofininhjelperproteiner
FI963164A0 (fi) Diabeteksen vastaisia peptidejä ja menetelmä
FI971085A0 (fi) Uusia PKA:ta sitovia proteiineja ja näiden käyttömuotoja
KR960010685A (ko) 펩티드 및 그 용도
GB2336844B (en) Anti-hiv peptides and proteins
FI955537A0 (fi) Fibrinolyyttiset ja hyytymistä estävät proteiinit
FI946031A (fi) Kringleä sisältävien proteiinien puhdistus ja etenkin t-PA:n
FI952108A0 (fi) Fibronnektiiniä sitova proteiini sekä sen valmistaminen
FI972791A (fi) Orgaanisten happojen ja aminohappojen valmistus
ZA9510752B (en) Aerosol formulations of peptides and proteins
BR1100734A (pt) Proteìna; proteìna ostogênica; e proteìna isolada

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20021231

KB4A Valid patent at the end of a year

Effective date: 20031231

KB4A Valid patent at the end of a year

Effective date: 20041231

KB4A Valid patent at the end of a year

Effective date: 20051231

KB4A Valid patent at the end of a year

Effective date: 20061231

KB4A Valid patent at the end of a year

Effective date: 20071231

HC1A Change of owner name
KB4A Valid patent at the end of a year

Effective date: 20081231

KB4A Valid patent at the end of a year

Effective date: 20091231

KB4A Valid patent at the end of a year

Effective date: 20101231

MM4A Lapsed by not paying the annual fees

Effective date: 20121219